Found 8 matching trials
Efficacy and Safety of G-202 in PSMA-Positive Glioblastoma
PHASE2Glioblastoma (GBM) comprises about 16% of all malignancies of the nervous s...
Location
John Wayne Cancer Institute
Continued Administration of G-202 for One Patient With Advanced Hepatocellular Carcinoma
N/APatient with advanced liver cancer (cancer that has spread to other parts o...
Status
No Longer Available
Location
Multiple Locations
Safety and Activity of G-202 in Patients With Clear Cell Renal Cell Carcinoma That Expresses PSMA
PHASE2An open-label, single-arm, single-center Phase II study to evaluate the saf...
Location
University of Texas Health Science Center, Houston
Dose-Escalation Phase 1 Study of G-202 (Mipsagargin) in Patients With Advanced Solid Tumors
PHASE1This is an open-label, single-arm, dose-escalation Phase I study to determi...
Location
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Study of G-202 (Mipsagargin) as Second-Line Therapy Following Sorafenib in Hepatocellular Carcinoma
PHASE2Hepatocellular carcinoma (HCC) is the fifth most common type of cancer worl...
Location
Mary Crowley Cancer Research Center
G-202 in the Neoadjuvant Setting Followed by Radical Prostatectomy in Patients With Prostate Cancer
PHASE2A single-arm, open-label Phase II clinical trial to evaluate the effect of ...
Location
University of Texas Health Sciences Center
Phase 2 Study of G-202 in Patients With Chemotherapy-NaΓ―ve Metastatic Castrate-Resistant Prostate Cancer
PHASE2Prostate cancer that has returned after local treatment usually responds to...
Location
The University of Texas Health Science Center
Efficacy, Safety and CNS Exposure of G-202 (Mipsagargin) in Patients With Recurrent or Progressive Glioblastoma
PHASE2This study will evaluate if a drug called G-202 can be safely used to treat...
Location
University of California, San Diego Moores Cancer Center